La cadena de opciones muestra datos clave de las opciones de acciones de CASI Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CASI Pharmaceuticals..

CASI Pharmaceuticals (NASDAQ:CASI) Bolsa, Cadena de Opciones

CASI Pharmaceuticals

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Inc

Casino Guichard-Perrachon SA

CASINO GUICHARD PERRACHON by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA ADR

CASIO COMPUTER CO LTD by Casio Computer Co., Ltd.

Casio Computer Co Ltd

CASIO COMPUTER UNSP/ADR by Casio Computer Co., Ltd.

CASI Pharmaceuticals Q3 Earnings Preview

Here's the major earnings before the open tomorrow

CASI Pharmaceuticals reports Q3 results

CASI Pharmaceuticals (CASI) has released an update. CASI Pharmaceuticals reported a 12% decrease in third-quarter revenue in 2024 compared to the p...

CASI Pharmaceuticals' Mixed Third-Quarter Performance in 2024

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Shares of Domino's Pizza (DPZ) w...

Berkshire reveals stake in Domino's, Alibaba reports mixed Q2: Morning Buzz

CASI Pharmaceuticals ( ($CASI) ) has issued an update. CASI Pharmaceuticals has received a Termination Process Letter from Acrotech Biopharma regar...

CASI Pharmaceuticals Faces Evomela® License Termination Dispute

17:39 EST Casi Pharmaceuticals (CASI) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...

Casi Pharmaceuticals files $200M mixed securities shelf

CASI Pharmaceuticals ( ($CASI) ) just unveiled an update. CASI Pharmaceuticals announced that the FDA has placed a clinical hold on its CID-103, an...

CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA

CASI Pharmaceuticals (CASI) announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-1...

Casi Pharmaceuticals announces first patient dosed in Phase 1/2 trial of CID-103

CASI Pharmaceuticals ( ($CASI) ) has provided an announcement. On January 21, 2025, CASI Pharmaceuticals announced that it received an asset freezi...

CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute

AFMD

ALHC

AMAT

AMZN

ASTS

AZUL

BABA

BILI

BLUE

BTAI

CASI

CRIS

CVSI

DESP

DTEGY

EONGY

HALO

ITRM

KEYUF

KNTNF

LUNR

MKGAF

NICE

NLCP

NTES

OCUL

ONEW

PAVM

PDSB

POLA

PVCT

QBTS

RCAT

SACH

SEDG

SIEGY

SLGL

SPCB

SSNLF

TRUG

TWLO

VEON

VISL

WKHS

XNET

Press Releases

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Small Cap

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Ligand Reports Second Quarter 2024 Financial Results

Earnings

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

News

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

AGEN

AMGN

LGND

MRNS

OVID

PIRS

TVTX

VKTX

VRNA

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

OncoCyte

OKYO Pharma

OS Therapies

Passage Bio

Q32 Bio

Rallybio

Rein Therapeutics

RenovoRx

Serina Therapeutics

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unity Biotechnology

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Exicure

Xilio Therapeutics

HC Wainwright & Co.

BTIG

Comments

CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) Opciones

CASI Pharmaceuticals (NASDAQ:CASI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL